NCT03940014View on ClinicalTrials.gov

Pulmonary Arteriovenous Malformations (PAVMs) in Hereditary Haemorrhagic Telangiectasia (HHT)

CompletedOBSERVATIONAL
Enrollment

170

Participants

Timeline

Start Date

January 1, 2014

Primary Completion Date

March 1, 2017

Study Completion Date

March 1, 2018

Conditions
Hereditary Haemorrhagic TelangiectasiaPulmonary Arteriovenous MalformationCerebral Disorder
Interventions
OTHER

Data collection from standard follow up

"Annual clinical consultation with an Hereditary Haemorrhagic Telangiectasia (HHT) specialist and/or pneumologist and organ specialists when necessary (such as hepatologists, cardiologists and neurologists).~Explorations (contrast echography, chest Computed Tomography and treatments performed according to international guidelines.~TransCatheter Embolotherapy for each treatable Pulmonary Arteriovenous Malformations (PAVMs) and follow-up every 3 years.~Chest Computed Tomography (CT) every 6-12 months."

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03940014 - Pulmonary Arteriovenous Malformations (PAVMs) in Hereditary Haemorrhagic Telangiectasia (HHT) | Biotech Hunter | Biotech Hunter